MOS has had one of its best weeks in months — a 14.8% rally to $24.27, built on a sharp short-covering move and a Q2 earnings beat that's resetting the narrative around fertilizer pricing and crop nutrient demand.
The most striking dynamic this week is the interplay between a retreating short position and a market that is nowhere near stressed in the lending pool. Short interest fell roughly 9% in a single session on August 25, dropping to 9.1% of the free float — still a meaningful bet against the stock, but clearly some bears are taking profits into the rally. That 9.1% level is about where shorts were camped in mid-July before they built higher through early August, peaking near 32 million shares around August 12-13. The reversal this week is sharp and clean, coinciding almost exactly with the post-earnings pop. Cost to borrow has edged up about 5% on the week to just 0.47% — still extremely cheap to borrow — and availability is running at roughly 760% of short interest, meaning there are around seven shares available to borrow for every one already lent out. The lending market is loose. There is no squeeze mechanism here; the bears who are covering are doing so on conviction, not necessity. Options positioning is calm in parallel: the put/call ratio at 0.67 is slightly above its 20-day average of 0.64 but only about one standard deviation from normal. That is not a market bracing for a reversal.
The Street is delivering a divided verdict. The most recent analyst move was a sharp one — on August 13, Freedom Broker cut MOS all the way from Buy to Sell and slashed its target from $32 to $17. That's a dramatic swing from the same analyst who had upgraded the stock in June. Morgan Stanley, which maintained Equal-Weight in late June while trimming its target to $26 from $28, is essentially saying the stock is fairly valued at current levels. The consensus mean target of $27.26 implies around 12% upside from the current price, but that number is dragged down by JPMorgan's long-standing Underweight with a $19 target and pulled up by Rothschild's June initiation at Buy with a $30 target. Bulls point to recovering phosphate volumes, the Esterhazy expansion's cost trajectory, and projected potash sales of 9.1 million tonnes in 2026. Bears counter with Brazilian demand weakness, high sulfur costs, and a history of production reliability misses at Riverview and Bartow. Valuation is genuinely cheap — price-to-book at 0.59 and EV/EBITDA at 6.2x — but the earnings yield factor score sits at just the 1st percentile for EPS surprise, meaning the company has not historically beaten estimates with any consistency. The 14-point drop in the PE ratio over the past week, now at 18x, reflects the price move more than any fundamental re-rating.
The institutional flow adds an interesting texture. AQR added roughly 7.3 million shares as of end-June, making it the third-largest holder at 5.7% of shares outstanding. Millennium essentially built its entire current position of 6.4 million shares in the same reporting period. Those are quant-oriented funds — their moves tend to track momentum and factor signals rather than fundamental thesis changes. With MOS up 15% on the week after being down 18% year-to-date heading into earnings, those positions are likely performing well. Sparinvest added over 4.5 million shares in the same window. The one insider transaction worth noting is modest: the Chief Administration Officer sold 23,000 shares at $22.12 on August 19, just before the earnings-driven jump. The timing is unremarkable in the context of a routine sale at a low-significance rating.
The Q2 earnings reaction delivered a 7.3% one-day gain and held nearly 6% over the following five days — the clearest positive print in the recent history data. The next earnings event is scheduled for November 6. Between now and then, the question is whether the post-earnings short-covering run has momentum behind it or whether bears rebuild at higher levels. At 9.1% of the float, short interest is still elevated enough to matter, and with borrow this cheap and availability this wide, rebuilding a position costs almost nothing.
What to watch: whether the short position continues to compress below 9% of the float in the days ahead, and whether any of the bellwether firms — Morgan Stanley or JPMorgan — revise their targets upward in response to the raised full-year guidance.
See the live data behind this article on ORTEX.
Open MOS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
